@Breakingviews
ReutersBreakingviews
3 months ago
Cutting out diseased parts can lead to a healthier prognosis. That’s presumably the thinking of Novartis Chief Executive Vas Narasimhan, who on Tuesday announced a review of the $207 billion drugmaker’s generics unit, writes @aimeedonnellan
Tweet media one
0
1
0